This is the fourth insider sale filing from the same officer within one week, signaling a routine option-exercise/cash-out cycle but at an elevated frequency. For a $1.5B biotech with no disclosed near-term catalyst, the concentrated selling is a modest negative signal. Monitor for additional Form 4 filings or a material change in corporate outlook that could explain the selling.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $57.77entry
- T+1 · 6mo ago −0.14%α −0.15% · $57.69
- T+5 · 6mo ago −11.27%α −12.48% · $51.26
- T+20 · 5mo ago +1.92%α +3.87% · $58.88
- T+60 · 3mo ago +2.58%α −0.15% · $59.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 10,000 shares of common stock, valued at approximately $593,008 based on the filing date price. This follows three prior sales in the same week totaling 35,467 shares for ~$2.16M, indicating a concentrated selling pattern by an insider.
Key Facts
- Form 144 filed on 2026-05-22 by officer Dennis Mulroy
- Proposed sale of 10,000 shares of common stock
- Estimated value: ~$593,008 at market price on filing date
- Shares acquired via stock option exercise on 05/22/2026 for cash
- Three prior open-market sales by Mulroy in the preceding week: 15,467 shares on 05/21 ($928k), 10,000 on 05/19 ($599k), 10,000 on 05/15 ($633k)
- Cumulative insider sales by Mulroy in the past week: ~45,467 shares for ~$2.75M
Financial Impact
Proposed additional sale of ~$593k; combined week of insider selling totals ~$2.75M against a $1.5B market cap
Risk Factors
- Insider selling may indicate lack of confidence in near-term share appreciation
- Biotech sector volatility could amplify any negative sentiment from insider sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-004947 |
| Document: 0001950047-26-004947-index.html | 0001950047-26-004947 |
| Document: 0001950047-26-004947.txt | 0001950047-26-004947 |
Track record
28 reports on ANAB
9 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 4/10 Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
- Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
- Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
- Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
- Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
- Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
- Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers